Fort Myers, Fla., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) has promoted Michelle Robey as Vice President of Marketing. She has served as FCS Director of Marketing & Communications since 2019. In this newly created senior leadership role, Robey directs all marketing and communications strategies and activities to strengthen the FCS brand and support the company’s long-term growth initiatives. She oversees branding, advertising, media and employee relations, and creative services for the statewide oncology practice.
“Michelle is a skilled and talented marketing communications professional with over 25 years of leadership experience in both healthcare and agency settings,” said FCS CEO Nathan H. Walcker. “Since joining FCS, she has devised and implemented numerous impactful external and internal initiatives and campaigns.”
FCS Chief Administrative Officer Joyce Nelson added, “Our selection committee enthusiastically concurred that Michelle is ideally suited to leading our efforts in this rapidly changing industry.”
Previously, Robey served for five years as Director of Marketing for AdventHealth Tampa and as Vice President of the Healthcare Provider Team with Hill & Knowlton Strategies in Tampa, and held progressive leadership positions with Humana Inc. and Norton Healthcare Inc. in Louisville, KY.
She holds a B.A. in Mass Communications and Political Science from Purdue University. Her numerous industry awards have included recognition from the American Marketing Association and from Healthcare Marketing Report. Michelle has served as an advisory board member for the University Area Community Development Center in Tampa.
###
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, MD Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies, and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians, and staff.
*Prior to approval
Attachment